Home > Neurology > AAN 2021 > Parkinson’s Disease and Other Movement Disorders > Novel non–D2-receptor-binding treatment for Parkinson’s disease psychosis

Novel non–D2-receptor-binding treatment for Parkinson’s disease psychosis

Presented By
Dr Stuart Isaacson, Parkinson's Disease and Movement Disorders Center of Boca Raton, FL, USA
Conference
AAN 2021
Parkinson’s disease psychosis (PDP) is a frequent, debilitating symptom of Parkinson’s disease and current treatments may worsen motor function. In a proof-of-concept study, a novel non–D2-receptor-binding treatment for PDP called SEP-363856 improved PDP symptoms without worsening the motor parkinsonism manifestations and was well tolerated. PDP is progressive, debilitating, and common, with a prevalence of around 60% as Parkinson’s disease progresses. Most treatment options are limited due to lack of efficacy, safety concerns, and/or exacerbation of motor symptoms. SEP-363856 is a full agonist of the TAAR1 and 5HT1A receptors. It is a potent regulator of dopamine neurotransmission and represents a novel way to prevent hyperactivity of the dopaminergic system. In a previous study, SEP-363856 demonstrated antipsychotic-like activity [1]. A proof-of-principle study evaluated safety and efficacy of SEP-363856 in PDP patients [2]. The results were shared by D...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on